Screener
United Therapeutics UTHR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from United Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: United Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001082554-26-000027
FAQ
- What is United Therapeutics's EBITDA margin?
- United Therapeutics (UTHR) reported EBITDA margin of 47.3% in Q2 2026.
- How has United Therapeutics's EBITDA margin changed year-over-year?
- United Therapeutics's EBITDA margin decreased by 4.6% year-over-year, from 49.6% to 47.3%.
- What is the long-term trend for United Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), United Therapeutics's EBITDA margin has grown at a 2.7% compound annual growth rate (CAGR), from 43.4% to 49.6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about United Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude